Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-30 02:42 | 2025-12-22 | EOLS | Evolus, Inc. | MOATAZEDI DAVID | Director, Officer | SELL | $7.15 | 10,539 | $75,361 | 354,388 |
| 2025-12-30 03:31 | 2025-12-23 | BNTC | Benitec Biopharma Inc. | SUVRETTA CAPITAL MANAGEMENT, LLC | Director, 10% owner | BUY | $13.20 | 144,223 | $1,903,138 | 1,848,156 |
| 2025-12-29 20:24 | 2025-12-24 | VSTM | Verastem, Inc. | Calkins Daniel | Officer | SELL | $7.86 | 80 | $629 | 109,758 |
| 2025-12-30 05:01 | 2025-12-24 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Officer | OPT+S | $42.00 | 15,000 | $630,005 | 88,787 |
| 2025-12-30 04:59 | 2025-12-24 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | Officer | SELL | $40.00 | 7,402 | $296,080 | 38,233 |
| 2025-12-30 05:11 | 2025-12-24 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Officer | SELL | $40.00 | 4,980 | $199,200 | 113,013 |
| 2025-12-30 05:05 | 2025-12-24 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Officer | OPT+S | $40.10 | 60,000 | $2,406,180 | 101,443 |
| 2025-12-30 01:16 | 2025-12-22 | MRUS | Merus N.V. | GENMAB A/S | 10% owner | BUY | $97.00 | 815,444 | $79,098,068 | 72,828,509 |
| 2025-12-30 02:42 | 2025-12-22 | EOLS | Evolus, Inc. | Avelar Rui | Officer | SELL | $7.15 | 2,261 | $16,168 | 356,821 |
| 2025-12-29 17:24 | 2025-12-24 | COCP | Cocrystal Pharma, Inc. | FROST PHILLIP MD ET AL | Director, 10% owner | BUY | $0.97 | 65,000 | $63,200 | 1,768,551 |
| 2025-12-30 04:42 | 2025-12-24 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Director | SELL | $44.55 | 33,356 | $1,486,010 | 3,561,655 |
| 2025-12-30 00:10 | 2025-12-29 | ALT | Altimmune, Inc. | Jorkasky Diane | Director | BUY | $3.80 | 527 | $2,003 | 527 |
| 2025-12-30 00:23 | 2025-12-23 | TXMD | TherapeuticsMD, Inc. | Thompson Tommy G | Director | BUY | $1.67 | 8,400 | $14,031 | 23,179 |
| 2025-12-29 16:10 | 2025-12-23 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Director, Officer | BUY | $1.02 | 5,000 | $5,100 | 286,421 |
| 2025-12-29 19:40 | 2025-12-23 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $2.60 | 4,100 | $10,660 | 0 |
| 2025-12-30 01:27 | 2025-12-22 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.64 | 291,283 | $185,227 | 2,550,674 |
| 2025-12-30 00:30 | 2025-12-24 | PTN | PALATIN TECHNOLOGIES INC | WILLS STEPHEN T | Officer | SELL | $16.74 | 565 | $9,461 | 63,488 |
| 2025-12-30 00:30 | 2025-12-22 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $514.35 | 22,500 | $11,572,963 | 0 |
| 2025-12-30 00:31 | 2025-12-24 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $513.18 | 11,000 | $5,644,954 | 36,781 |
| 2025-12-30 04:44 | 2025-12-24 | SION | Sionna Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director | SELL | $44.55 | 33,356 | $1,486,010 | 3,561,655 |
| 2025-12-30 00:09 | 2025-12-24 | DVAX | Dynavax Technologies Corporation | Novack David F | Officer | OPT+S | $15.49 | 30,000 | $464,700 | 111,451 |
| 2025-12-24 00:02 | 2025-12-22 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | Officer | OPT+S | $18.31 | 9,200 | $168,492 | 145,355 |
| 2025-12-23 16:18 | 2025-12-22 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | BUY | $1.22 | 57,189 | $69,999 | 1,421,478 |
| 2025-12-23 16:14 | 2025-12-22 | MAIA | MAIA Biotechnology, Inc. | Louie Ngar Yee | Director | BUY | $1.22 | 81,699 | $100,000 | 1,248,888 |
| 2025-12-24 02:01 | 2025-12-19 | ARWR | Arrowhead Pharmaceuticals Inc. | Vakiener Victoria | Director | SELL | $67.68 | 10,040 | $679,491 | 35,723 |
| 2025-12-24 00:37 | 2025-12-19 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $6.49 | 9,949 | $64,564 | 383,201 |
| 2025-12-23 16:16 | 2025-12-22 | MAIA | MAIA Biotechnology, Inc. | CHAOUKI STEVEN M | Director | BUY | $1.22 | 40,849 | $49,999 | 151,873 |
| 2025-12-24 05:40 | 2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | Zojwalla Naseem | Officer | OPT+S | $27.94 | 269,509 | $7,530,135 | 4,488 |
| 2025-12-24 05:41 | 2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | Officer | SELL | $30.46 | 51,000 | $1,553,542 | 551,881 |
| 2025-12-24 00:24 | 2025-12-23 | EQ | Equillium, Inc. | Zedelmayer Christine | Officer | OPT+S | $1.50 | 100,000 | $150,000 | 91,444 |
| 2025-12-24 02:45 | 2025-12-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $16.84 | 5,000 | $84,206 | 897,688 |
| 2025-12-24 04:48 | 2025-12-23 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Firestone Karen | Director | BUY | $12.45 | 8,100 | $100,845 | 63,100 |
| 2025-12-24 04:08 | 2025-12-22 | OKUR | OnKure Therapeutics, Inc. | Leverone Jason A. | Officer | SELL | $2.97 | 302 | $896 | 16,301 |
| 2025-12-24 04:09 | 2025-12-22 | OKUR | OnKure Therapeutics, Inc. | Saccomano Nicholas A | Director, Officer | SELL | $2.97 | 87 | $258 | 7,419 |
| 2025-12-24 02:01 | 2025-12-19 | ARWR | Arrowhead Pharmaceuticals Inc. | Waddill William D. | Director | SELL | $67.65 | 8,367 | $566,038 | 56,563 |
| 2025-12-24 02:52 | 2025-12-22 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Director | OPT+S | $80.00 | 5,000 | $400,000 | 0 |
| 2025-12-24 00:41 | 2025-12-22 | IMNM | Immunome Inc. | Barchas Isaac | Director | SELL | $21.74 | 383,200 | $8,330,078 | 2,031,181 |
| 2025-12-24 02:01 | 2025-12-19 | ARWR | Arrowhead Pharmaceuticals Inc. | Anzalone Christopher Richard | Director, Officer | SELL | $68.04 | 26,031 | $1,771,022 | 3,805,926 |
| 2025-12-24 00:30 | 2025-12-23 | ANAB | AnaptysBio Inc. | Ware J. Anthony | Director | SELL | $49.58 | 3,900 | $193,343 | 9,630 |
| 2025-12-24 00:28 | 2025-12-22 | ANAB | AnaptysBio Inc. | Lizzul Paul F. | Officer | OPT+S | $50.00 | 1,500 | $75,000 | 26,967 |
| 2025-12-24 05:42 | 2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | CLARK IAN T | Director | OPT+S | $29.73 | 264,800 | $7,873,113 | 0 |
| 2025-12-24 00:30 | 2025-12-19 | ALZN | Alzamend Neuro Inc. | Horne William B. | Director | SELL | $2.12 | 3,333 | $7,059 | 0 |
| 2025-12-24 00:02 | 2025-12-19 | XNCR | Xencor Inc | Desjarlais John R | Officer | OPT+S | $15.72 | 73,367 | $1,153,329 | 236,574 |
| 2025-12-24 00:01 | 2025-12-19 | XNCR | Xencor Inc | Dahiyat Bassil I | Director, Officer | OPT+S | $15.71 | 114,377 | $1,796,863 | 466,635 |
| 2025-12-24 00:10 | 2025-12-23 | ALT | Altimmune, Inc. | GILL JOHN | Director | BUY | $4.10 | 12,500 | $51,250 | 12,500 |
| 2025-12-23 22:04 | 2025-12-22 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $2.67 | 5,673 | $15,168 | 0 |
| 2025-12-24 00:28 | 2025-12-22 | ANAB | AnaptysBio Inc. | MULROY DENNIS | Officer | OPT+S | $50.00 | 10,000 | $500,000 | 9,401 |
| 2025-12-24 02:01 | 2025-12-19 | ARWR | Arrowhead Pharmaceuticals Inc. | OLUKOTUN ADEOYE Y | Director | SELL | $67.66 | 10,000 | $676,623 | 33,600 |
| 2025-12-24 02:50 | 2025-12-19 | MIRM | Mirum Pharmaceuticals, Inc. | GREY MICHAEL G | Director | OPT+S | $78.00 | 50,000 | $3,900,000 | 0 |
| 2025-12-24 00:27 | 2025-12-22 | ANAB | AnaptysBio Inc. | LOUMEAU ERIC J | Officer | OPT+S | $51.00 | 10,000 | $510,000 | 8,947 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.